Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights

Get insights on Emcure Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Emcure Pharmaceuticals Ltd Share Price Chart

Emcure Pharmaceuticals Ltd Fundamentals

Traded Volume: 3,53,292

Market Cap(Cr): 26,149

Avg Traded Price 1297.94

1 Year return %

Upper Circuit 1,419.4

Lower Circuit 1,343.2

P/E TTM 33.00

P/B Ratio 42.00

Traded Value(Cr) 4873.31

EPS TTM 41.838

Book value 41.838

Dividend 0.00%

Emcure Pharmaceuticals Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Emcure Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Emcure Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +1.50%

1M +0.64%

3M -2.07%

1Y null%

YTD -8.41%

Emcure Pharmaceuticals Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Emcure Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 2.03L

Day Before Yesterday 4.34L

1W Avg 4.26L

1M Avg 1.77L

3M Avg 1.30L

Emcure Pharmaceuticals Ltd Technical Details

Emcure Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 1302

Support 2 1267

Support 3 1214

Pivot Point : 1355

Resistance 1 1390

Resistance 2 1443

Resistance 3 1478

Emcure Pharmaceuticals Ltd Corporate Actions

Emcure Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Emcure Pharmaceuticals Ltd’s capital allocation strategies.

All

Ex-Date 14-Aug-2025 Type D Description 3.00/share@30.00% Record Date 14-Aug-2025 Ratio 30.00

Dividends

Announcement Date 14-Aug-2025 Ex Dividend Date 14-Aug-2025 Dividend(%) 30

Bonus

No Bonus has been declared by EMCURE

Splits

No Split has been declared by EMCURE

Others

Rights No Rights has been declared by EMCURE

Emcure Pharmaceuticals Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Emcure Pharmaceuticals Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Emcure Pharmaceuticals Ltd's relative performance and valuation against major competitors.

Stock Name Gland Pharma Ltd ₹1829.20 (-0.47%) M. Cap (Cr) 301.37 1 Yr Return (%) +3.66% P/E (TTM) 38.13 PB Ratio 3.29

Stock Name J B Chemicals & Pharmaceuticals Ltd ₹1818.60 (-0.05%) M. Cap (Cr) 284.79 1 Yr Return (%) +2.19% P/E (TTM) 39.64 PB Ratio 8.87

Stock Name Syngene International Ltd ₹662.10 (-0.26%) M. Cap (Cr) 266.79 1 Yr Return (%) -25.55% P/E (TTM) 56.98 PB Ratio 6.07

Stock Name Emcure Pharmaceuticals Ltd ₹1379.40 (+3.14%) M. Cap (Cr) 261.49 1 Yr Return (%) NaN% P/E (TTM) 32.97 PB Ratio 6.35

Stock Name Piramal Pharma Ltd ₹193.84 (-0.92%) M. Cap (Cr) 257.66 1 Yr Return (%) -22.65% P/E (TTM) -1085.33 PB Ratio 3.26

Stock Name Cohance Lifesciences Ltd ₹629.10 (-8.81%) M. Cap (Cr) 240.67 1 Yr Return (%) -47.77% P/E (TTM) 97.10 PB Ratio 14.08

Stock Name Astrazeneca Pharma India Ltd ₹9183.00 (-1.07%) M. Cap (Cr) 229.58 1 Yr Return (%) +24.02% P/E (TTM) 115.28 PB Ratio 33.79

Emcure Pharmaceuticals Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Emcure Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 558.28 Mar 2024 584.97 Mar 2023 505.37 Mar 2022 427.71 Mar 2021 774.87

PARTICULARS Investing Activities Mar 2025 -435.61 Mar 2024 -171.08 Mar 2023 -270.44 Mar 2022 -189.00 Mar 2021 -831.16

PARTICULARS Financing Activities Mar 2025 -49.25 Mar 2024 -287.75 Mar 2023 -54.52 Mar 2022 -342.96 Mar 2021 30.97

PARTICULARS Net Cash Flow Mar 2025 71.38 Mar 2024 124.15 Mar 2023 180.30 Mar 2022 -309.06 Mar 2021 -29.94

Emcure Pharmaceuticals Ltd Shareholding Pattern

This shows the ownership breakdown of Emcure Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 77.88%

Public 14.46%

Other Institutions 0.78%

FII 3.29%

Mutual Funds 3.58%

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as `Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to `Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broadrange of pharmaceutical products across several major therapeutic areas. In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics. The Company has 13 manufacturing facilities across India. It keeps a strong track record in developing portfolios of differentiated products, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far.In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during the period 2001. The Company established facility in Kurkumbh in 2006 and then started operations of injectables facility in Hinjawadi. The facility established by Company's Subsidiary, Gennova Biopharmaceuticals Limited at Hinjawadi became operational.The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018. The subsidiary, Tillomed France S.A.S., was incorporated in France in 2018. The Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile in 2020. The Company has a portfolio of six commercialized and in-house manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase,commonly used for acute myocardial infraction, and the biosimilar for Pegylated-asparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021 and Emcure Pharma Philippines Inc., incorporated in Philippines in 2021-22. Tillomed Malta Ltd, was incorporated in Malta in 2022-23. In July 2024, the Company came up with an Initial Public Offer of issuing 19,375,070 Equity Shares aggregating to Rs 1952.02 Crore comprising a Fresh Issue of 7,946,231 Equity Shares aggregating to Rs 800 Crore and an Offer for Sale of 11,428,839 Equity Shares aggregating to Rs 1152.02 Crore.In FY2025, Emcure entered this high-growth sector with the launch of Emcutix Biopharmaceuticals, a wholly owned subsidiary that consolidates its dermatology operations. The Company entered the fast-growing consumer health segment under the 'Arth' brand, targeting lifestyle and wellness categories with science-backed formulations.

Whole Time Director

MUKUND KESHAO GURJAR

Registered office Plot # P-1 & P-2 IT BT Park, Phase II MIDC Hinjawadi, Pune, Maharashtra, 411057

FAX :+91 20 3507 0033/+91 20 3507 0000

Background

Incorporation Year 1981

Face Value ₹10.00

Market Lot 1

Emcure Pharmaceuticals Ltd Latest News

VIEW MORE NEWS

FAQs on Emcure Pharmaceuticals Ltd